As a physician-scientist, I have been part of the Side-Out trial since 2009. The major goal of the trial is the improvement of survival rates of metastatic breast cancer patients through the delivery of what is known as “precision medicine.” But what does the term really mean? I have spent hundreds of hours at the […]
The Side-Out Protocol: A Scientist’s Perspective Read More »
Recently, Emanuel Petriocoin and Lance Liotta of George Mason University’s (GMU) Center for Applied Proteomics & Molecular Medicine (CAPMM) discovered that activation of the protein ALK (anaplastic lymphoma kinase) is associated with inflammatory breast cancer, a particularly aggressive form of the disease: “Mason Research Gives Hope to Women With Deadliest Breast Cancer”. Although this study
New Research on Inflammatory Breast Cancer Read More »
The Side-Out Foundation, which pairs volleyball enthusiasts with breast cancer researchers, is sponsoring a new clinical trial for up to 25 patients with advanced breast cancer. TGen Drug Development (TD2) will manage this pilot study for the Side-Out Foundation at two locations: TGen Clinical Research Services (TCRS) at Scottsdale Healthcare in Scottsdale, Ariz.; and Fairfax
Side-Out Foundation Hopes to Score Big: 1st Breast Cancer Clinical Trial Read More »
Dig Pink Volleyball Breast Cancer Awareness Campaign aims to raise $1 million.
Side-Out Protocol Press Release! Read More »
GMU, With Ties to Italy, Aims to Be a Biotech Force By Michael Laris Wednesday, February 27, 2008; B01 The tiny pieces of tumor, cut from 51 Italian cancer patients, arrived at a suburban Washington laboratory in boxes packed with dry ice. Doctors at the University of Padua had frozen 51 nubs of tissue taken
In a Va. Lab, Forging Links to Speed Cancer Advances Read More »
Side-Out is a proud member of the
© The Side-Out Foundation is a 501(c)(3) non-profit organization. EIN 20-2510044
Dig Pink® is a registered trademark of the Side-Out Foundation
